Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT02446236Phase 1Active, not recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Hackensack Meridian Health. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2015; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02446236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446236.